Improved reperfusion and vasculoprotection by the poly (ADP-ribose) polymerase inhibitor PJ34 after stroke and thrombolysis in mice

M El Amki, D Lerouet, M Garraud, F Teng… - Molecular …, 2018 - Springer
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …
被引用次数：31 相关文章

Improved Reperfusion and Vasculoprotection by the Poly (ADP-Ribose) Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.

M El Amki, D Lerouet, M Garraud, F Teng… - Molecular …, 2018 - europepmc.org
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …

Improved Reperfusion and Vasculoprotection by the Poly (ADP-Ribose) Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice

M El Amki, D Lerouet, M Garraud, F Teng… - Molecular …, 2018 - hero.epa.gov
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …

Improved Reperfusion and Vasculoprotection by the Poly (ADP-Ribose) Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice

M El Amki, D Lerouet, M Garraud, F Teng… - Molecular …, 2018 - search.proquest.com
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …

Improved Reperfusion and Vasculoprotection by the Poly (ADP-Ribose) Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice

M El Amki, D Lerouet, M Garraud… - Molecular …, 2018 - pubmed.ncbi.nlm.nih.gov
Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after
ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates …